Gilead Sciences joins the ABPI

Gilead Sciences has joined the membership of the Association of the British Pharmaceutical Industry, effective from January 2022.

The company represents a significant addition to the ABPI membership and has a strong track record of advancing care for patients around the world by bringing forward medicines in areas of unmet medical need across a range of therapy areas.

Operating in 35 countries around the world, the company has a particular focus on delivering care for cancer, viral hepatitis, and HIV.

The ABPI’s membership now represents over 90% of the branded medicines market in the UK. It now has 63 full member companies, including the top 15 of the world’s biggest pharmaceutical companies.

As it looks to the future, the ABPI is working across a number of important policy areas, both globally and domestic, including tackling future health crises and shaping important international issues around trade and future regulation.

The industry is set to play a key role, working with partners in the government and the NHS, to help build back NHS services and a more resilient health service post-pandemic, with a priority to ensure NHS patients can be among the first in the world to get access to new and innovative medicines now and in the future.

The addition of Gilead Sciences to an already strong coalition of members should ensure the ABPI is best placed to deliver those ambitions.

Dr Véronique Walsh, General Manager & VP - UK & Ireland, Gilead Sciences, said: 

“I’m thrilled Gilead Sciences is joining the ABPI. 

"It has never been a more exciting time to be working in medicines development and at Gilead, we are focussed on delivering innovation which transforms the lives of patients. 

"By joining forces with the ABPI we believe we can bring the next generation of life-changing treatments to NHS patients and help the UK to become one of the world’s leading locations for life sciences.”

Richard Torbett, Chief Executive of the ABPI, said:

“I’m delighted to welcome Gilead Sciences as a member of the ABPI.

“They are a world-leading pharmaceutical company, bringing innovative new treatments to patients around the world.  I am excited to work with them as part of the ABPI, as we look to build on the strengths of the UK’s life science sector.

“The ABPI now represents over 90 per cent of the UK’s branded medicines market, putting us in an even stronger place to deliver on our ambitions and to support the NHS as we recover from the COVID-19 pandemic.”